Reduced MEC differentiation measured by a decrease in expression of Cnn1 and Acta2 also precedes the progression of in situ ductal carcinoma to invasive disease in mammary gland32–34; thus, the clinical impact of targeting MEC differentiation may expand beyond SG regeneration. Here, ACTA2 is linked to ductal breast carcinoma in situ.